Incapacitating solar urticaria: successful treatment with omalizumab
An. bras. dermatol
; 94(3): 331-333, May-June 2019. graf
Article
em En
| LILACS
| ID: biblio-1011115
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
Palavras-chave
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Luz Solar
/
Urticária
/
Antialérgicos
/
Omalizumab
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
Limite:
Humans
/
Male
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article